MNG279
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.332
- INTERFERON_ALPHA_RESPONSE+0.297
- PANCREAS_BETA_CELLS+0.235
- INTERFERON_GAMMA_RESPONSE+0.221
- TNFA_SIGNALING_VIA_NFKB+0.212
- COAGULATION+0.211
- ESTROGEN_RESPONSE_LATE+0.174
- HEDGEHOG_SIGNALING+0.167
- ALLOGRAFT_REJECTION+0.161
- MYOGENESIS+0.125
Top 10 suppressed
- E2F_TARGETS-0.487
- G2M_CHECKPOINT-0.457
- DNA_REPAIR-0.432
- MYC_TARGETS_V2-0.417
- MITOTIC_SPINDLE-0.361
- MYC_TARGETS_V1-0.360
- PI3K_AKT_MTOR_SIGNALING-0.351
- PROTEIN_SECRETION-0.321
- UNFOLDED_PROTEIN_RESPONSE-0.282
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NT9NZYFD | Ganglioglioma | — | 0.902 |
| 2 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.855 |
| 3 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.851 |
| 4 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.851 |
| 5 | MDT-AP-0746 | Med | Medulloblastoma | 0.847 |
| 6 | TCGA-CF-A47S-01A-11R-A23W-07 | — | — | 0.846 |
| 7 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.845 |
| 8 | 8bcf201b-a2ac-4026-ace4-39a0d915da41 | — | — | 0.845 |
| 9 | C3N-03038 | — | cohortA1 | 0.838 |
| 10 | SRR1358826 | GTEX | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.332 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.297 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.235 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.221 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.212 | Inavolisib | — uncovered |
| COAGULATION | 0.211 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.174 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.167 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.161 | Idelalisib | — uncovered |
| MYOGENESIS | 0.125 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.103 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.098 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.097 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.095 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.076 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.069 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.052 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.041 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.041 | Inavolisib | — uncovered |